Biodesix Completes $22M Series F Round | GenomeWeb

NEW YORK (GenomeWeb) – Biodesix said today that it has completed a $22 million Series F financing round.

The company raised most of the funds through the sale of preferred stock and other securities — the total amount also includes capital previously raised through convertible debt that was converted into equity in this round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.